Search Results
10
Everything
Search Filters
Organization
Daré Bioscience, Inc.
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
March 31, 2025 16:01 ET
|
Daré Bioscience, Inc.
Enables women to access a solution that they want and needCreates an opportunity to accelerate revenue generation from this proprietary formulation Daré expects to start recording revenue and cash...
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
March 24, 2025 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at...
Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
February 20, 2025 08:00 ET
|
Daré Bioscience, Inc.
Ongoing Phase 1 study is funded by a foundation grant Daré received a royalty-free, exclusive license to the US patents SAN DIEGO and LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) --...
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
February 06, 2025 08:00 ET
|
Daré Bioscience, Inc.
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management Essentially all...
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
January 09, 2025 08:00 ET
|
Daré Bioscience, Inc.
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of...
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
December 16, 2024 08:00 ET
|
Daré Bioscience, Inc.
FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA...
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
December 10, 2024 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that additional data from the...
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
December 04, 2024 08:00 ET
|
Daré Bioscience, Inc.
Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering...
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
November 14, 2024 16:01 ET
|
Daré Bioscience, Inc.
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3...
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
November 13, 2024 08:00 ET
|
Daré Bioscience, Inc.
- Grant funds will support activities that will aid in the identification and development of a novel non-hormonal intravaginal contraceptive product candidate. - Grant will also provide funding to...